Low-Level Laser Therapy (Photobiomodulation) in Knee Meniscus Injury Rehabilitation

A Comprehensive Literature Review

Prepared: 2026-09-28 Style: Vancouver numbered citations (all 59 PMIDs mechanically verified via NCBI E-utilities esummary on the date of preparation; ClinicalTrials.gov entries verified via the ClinicalTrials.gov v2 API on the same date; searcher-mediated verification conducted against EuropePMC REST and NCBI E-utilities) Note: This review is prepared for personal knowledge; all factual claims carry citation numbers resolved in the reference list. Statistics are reproduced only where they could be verified against primary metadata/abstracts; figures that could not be verified are explicitly flagged or rejected.


Abstract

Knee meniscal injuries are among the most common musculoskeletal problems seen in primary care, sports medicine, and orthopedic practice, and rehabilitation is the foundation of management for the large majority of non-obstructive and degenerative tears [5,7,8,9,13]. Low-level laser therapy (LLLT) — increasingly termed photobiomodulation (PBM) — is a non-invasive, non-ablative light-based modality with plausible biological rationale for meniscal rehabilitation: near-infrared/red light absorbed by mitochondrial cytochrome c oxidase modulates cellular metabolism, inflammation, and matrix synthesis, and a growing in vitro and animal literature documents dose-dependent proliferative and chondrogenic responses in meniscus-derived stem cells and protective effects on articular cartilage [16,17,18,19,22,24]. This review synthesizes the full evidence chain for LLLT in knee meniscus injury rehabilitation: (1) the anatomy, vascularity, and healing biology of the meniscus; (2) the mechanisms of action of photobiomodulation; (3) the preclinical and translational evidence on meniscal fibro-chondroprogenitor and cartilage responses; (4) the direct clinical evidence in meniscal pathology, which rests on exactly two small randomized, double-blind, placebo-controlled trials — Malliaropoulos et al. 2013 (n≈64) and Alsirhani 2026 (n=40), the latter being the seed publication for this review — both reporting significant pain and function gains with LLLT added to non-operative care [2,34,35]; (5) the adjacent and much larger knee osteoarthritis evidence base, including conflicting meta-analyses (Bjordal 2007 positive; Huang 2015 negative; Stausholm 2019 positive with a dose-response; Li 2024 positive for WOMAC outcomes) [36,37,38,39]; (6) dose-response relationships and World Association for Laser Therapy (WALT) consensus parameters [15,38]; (7) safety considerations, including the critical distinction between therapeutic LLLT and the historically abandoned surgical (ablative) lasers used for meniscectomy, which produced chondral injury and osteonecrosis [54,55,56,57,58,59]; and (8) the trial-registration landscape. Conclusions: direct evidence for LLLT in meniscal injury is encouraging but thin — two small positive RCTs, no replication at scale, heterogeneous protocols, and no dedicated ongoing meniscus-specific PBM trial identified as of September 2026 in ClinicalTrials.gov [60,61,62]. The most defensible clinical position is that LLLT is a safe, low-risk adjunct to structured rehabilitation for symptomatic meniscal injuries (including post-operative recovery), provided WALT-consistent dosing is used; claims of meniscal structural healing or disease modification currently exceed the evidence [30,32,33].


1. Introduction and Historical Context

The menisci of the knee are two wedge-shaped, semilunar fibrocartilaginous structures — the medial and lateral meniscus — that transmit the majority of the load across the tibiofemoral joint in extension and distribute stresses across the articular cartilage [1,2,3]. They are not inert spacers: the menisci contribute to joint stability, shock absorption, proprioception, and lubrication, and they deepen the tibial articulation for the femoral condyles [1,3]. Their biological vulnerability is structural: only the peripheral (outer) third of the meniscus is vascularized, and healing potential tracks that vascularity — peripheral “red-red” tears may heal, while tears of the inner avascular two-thirds, and most complex/degenerative tears, have little intrinsic repair capacity [2,3]. Nociceptors and mechanoreceptors are concentrated in the outer two-thirds, which explains both the pain-generating potential of tears that reach the periphery and the relative painlessness of central degeneration [3,4].

Meniscal injury is common and age-dependent. Magnetic resonance imaging of asymptomatic volunteers reveals meniscal tears in roughly 16% of people overall, rising from approximately 13% in those younger than 45 years to 36% in those older than 45 [5]. The MRI grading system of Stoller and colleagues (grades 1–3 intrasubstance signal) remains the standard framework for interpreting meniscal signal, with grade 3 signal that contacts an articular surface representing a tear [4]. The clinical paradigm for meniscal tears has shifted markedly in two decades. Randomized trials have shown that arthroscopic partial meniscectomy provides no advantage over sham surgery in middle-aged and older adults with degenerative meniscal tears — the Finnish FIDELITY trial (Sihvonen et al. 2013, n=146; with 2-year and 5-year follow-ups confirming the null result) — and no long-term advantage over structured physical therapy in patients with a meniscal tear and osteoarthritis (Katz et al. 2013, MeTeOR) [7,8,9,11]. A secondary analysis of the Finnish trial found that even “mechanical symptoms” (catching, locking) did not justify surgery in most patients [10]. Long-term consequences of meniscectomy are well documented: a landmark study reported radiographic knee osteoarthritis in roughly half of patients at a mean of 21 years after meniscectomy when compared with matched controls, underscoring the importance of meniscal preservation [6]. These findings have reoriented practice toward non-operative care (rehabilitation, activity modification, injectable therapies), meniscal repair where anatomy permits, and a more conservative threshold for arthroscopic resection [12,13,14,15].

It is within this conservative-first framework that low-level laser therapy has been proposed as an adjunct to rehabilitation for meniscal injuries. The seed publication for this review — Alsirhani 2026, Lasers in Medical Science — is a randomized, double-blind, placebo-controlled trial of LLLT in 40 adults with MRI-confirmed meniscal injuries, reporting that LLLT added to a six-week standardized rehabilitation program produced greater reductions in pain and greater improvements in knee function, mobility, and range of motion than rehabilitation alone (p<0.01 for all outcomes), with effects exceeding clinically meaningful thresholds [35]. The remainder of this review establishes the mechanistic and evidentiary context in which that single trial must be interpreted.

This review is structured around eight questions: (1) What is the meniscus, and why does it not heal reliably? (2) What is photobiomodulation, and why is its biology plausible for meniscal tissue? (3) What do preclinical and translational studies show in meniscal and cartilage tissue? (4) What is the direct clinical evidence in meniscal injury? (5) What does the adjacent knee-osteoarthritis evidence base contribute? (6) What doses and parameters are recommended and what does dose-dependence mean? (7) Is LLLT safe, and how does it differ from surgical lasers in meniscus surgery? (8) What are the evidence gaps, registry landscape, and defensible clinical conclusions?


2. The Meniscus: Biology, Injury, and the Rehabilitative Context

2.1 Structure, Vascularity, and Healing

The meniscus is ~70–80% water, with type I collagen predominating in the fibrocartilaginous matrix, oriented circumferentially to convert vertical loads into hoop stress [1,3]. The embryologically and biologically distinct zones matter clinically: the peripheral third has a blood supply (perimeniscal capillary plexus from the medial and lateral geniculate arteries), the middle third has a limited transitional supply, and the inner third is avascular [2,3]. Tear location relative to these zones predicts healing after repair and explains why partial meniscectomy, though biomechanically straightforward, sacrifices load-bearing function [2,3,12]. The menisci are innervated by mechanoreceptive and nociceptive fibers in the horns and outer third, and meniscal pathology can therefore produce localized and referred knee pain independent of chondral disease [3].

2.2 Epidemiology, Diagnosis, and the Conservative-First Paradigm

Meniscal tears are detected at asymptomatic baseline rates of 13–36% by age [5], and symptomatic tears are diagnosed clinically with the aid of MRI, where the Stoller grading system remains the reference framework [4]. The management revolution of the 2010s is now firmly established: for non-obstructive degenerative tears in middle-aged and older adults, arthroscopic partial meniscectomy offers no benefit over sham or over physical therapy [7,8,9,10,11]. Even in the presence of mechanical symptoms, the Finnish trial’s secondary analysis did not support routine arthroscopy [10]. Meniscal repair, by contrast, is favored when tears are peripheral, reparable, and in younger patients, and is more cost-effective overall than resection in appropriate candidates [12,14]. For degenerative tears and in older adults, rehabilitation and delayed arthroscopy are more cost-effective than early meniscectomy [14]. The 2019 American College of Rheumatology/Arthritis Foundation guideline for hand, hip, and knee osteoarthritis strongly endorses exercise and weight-loss interventions; no specific recommendation on low-level laser therapy appears in the guideline, a point that requires explicit acknowledgment [15]. Within this conservative-first framework, rehabilitation — including strengthening, neuromuscular control, and graded return to activity — is the backbone of care, and adjunctive physical modalities are only defensible if they add measurable value [15].


3. Photobiomodulation: Definition and Mechanisms of Action

3.1 Terminology and Physics

Low-level laser therapy (LLLT), low-intensity laser therapy, “cold” laser, and, increasingly, photobiomodulation (PBM) or photobiomodulation therapy (PBMT) all refer to the therapeutic application of low-power red (≈600–700 nm) or near-infrared (≈780–1100 nm) light to tissue for biological rather than thermal effect [16,17]. The mechanism is photochemical, not thermal: photon absorption in cells drives redox and signaling changes without tissue heating, in contrast to surgical lasers, which ablate or cauterize (Section 8). Energy delivery is characterized by wavelength (nm), power density/irradiance (mW/cm²), energy density/fluence (J/cm²) or total dose per point (J), spot size, and treatment schedule [15,16,18,38]. The World Association for Laser Therapy (WALT) published a consensus agreement in 2006 on the design and conduct of clinical studies with LLLT for musculoskeletal pain, establishing dose-reporting standards [18].

3.2 Cellular Mechanisms

The canonical mechanism, elaborated by Karu, is absorption of red/NIR light by cytochrome c oxidase (complex IV) of the mitochondrial electron transport chain, increasing mitochondrial membrane potential, ATP synthesis, and generation of low levels of reactive oxygen species (ROS) that act as signaling molecules [16]. This “mitochondrial retrograde signaling” activates transcription factors and downstream pathways including NF-κB modulation (anti-inflammatory under chronic, low-level stimulation), PI3K/Akt/mTOR proliferation and survival signaling, and Nrf2-mediated antioxidant responses [16,17]. Hamblin’s 2017 synthesis of the anti-inflammatory actions of photobiomodulation emphasizes the induction of transforming growth factor-β (TGF-β), IL-10, and the suppression of pro-inflammatory mediators including TNF-α and IL-1β, driven centrally by low-level ROS and cyclic-AMP/NO signaling [17]. These effects are dose- and irradiance-dependent, with a well-recognized biphasic “Arndt-Schulz-like” relationship: too little energy has no effect, and too much may suppress the beneficial response [16,17,29].

3.3 Relevance to Meniscal and Chondral Tissue

Three lines of mechanistic evidence are directly relevant to meniscus rehabilitation:

  • Effect on fibrocartilage/chondral cells. Low-level Nd:YAG laser energy at 51–127 J/cm² transiently stimulated matrix (proteoglycan) synthesis in adult cartilage explants in culture, with the effect dissipating by 12–14 days — an early demonstration that laser energy can upregulate cartilage matrix metabolism in a dose-dependent way [19]. More recent in vitro work shows LLLT increases type I collagen synthesis in early ligament-fibroblast healing [20].
  • Meniscus-derived stem cells (MeSCs). In 2024, Tong and colleagues showed that 660-nm LED photobiomodulation at 18 J/cm² (vs. 4 J/cm² or control) increased the proliferation, mitochondrial activity, and chondrogenic differentiation capacity of human MeSCs, with upregulation of Akt, PI3K, TGF-β3, Ki67, Notch-1, Col2A1, Sox9, and Aggrecan [21]. A 2025 follow-up established a dose- and wavelength-dependent effect of PBM on MeSC mitochondrial function and proliferation mediated through TRPV1-channel Ca²⁺ and ROS signaling, with the most robust proliferation responses at 700–710 nm and 1064 nm and 3–30 J/cm² (best at 15 J/cm²), while other parameter sets reduced mitochondrial function — a mechanistically explicit demonstration that meniscal progenitor responses are parameter-sensitive [22].
  • Inflammatory modulation in the joint. Photobiomodulation mitigated chondrocyte catabolism in osteoarthritis by modulating macrophage M1 polarization through the IL-6/JAK/STAT pathway, indicating that PBM can act on synovial/macrophage inflammation in ways relevant to the inflammatory milieu of acute meniscal injury [23].

4. Preclinical and Translational Evidence

4.1 Knee-Osteoarthritis Animal Models

A consistent body of rabbit and rat work shows LLLT reduces pain behavior, synovitis, and cartilage catabolism and preserves matrix anabolism:

  • Wang et al. 2014 (rabbit ACL-transection OA model, n=160): LLLT at 830 nm, 1.5 J/cm², three times weekly, reduced knee pain and synovitis after ≥6 weeks, protected the medial femoral condyle at 6 weeks and both condyles plus the medial tibial plateau at 8 weeks, decreased IL-1β, iNOS, and MMP-3, and slowed loss of TIMP-1, collagen II, aggrecan, and TGF-β [24].
  • Guo et al. 2011 (rabbit knee OA, eight physical modalities): low-level laser therapy was among the modalities that reduced serum TNF-α, decreased chondrocyte apoptosis and caspase-3/-8 expression, and improved cartilage structure [25].
  • Assis et al. 2016 (rat knee OA): combined aerobic exercise training and LLLT modulated inflammatory response and degeneration in articular cartilage better than either alone — evidence supporting the combination of PBM with exercise, the exact paradigm used in meniscal rehabilitation [26].
  • Fan et al. 2025 (chondrocytes and a destabilization-of-medial-meniscus mouse model): 940-nm LED at 52 J/cm² best suppressed MMP-3/MMP-13 and restored Col2A1/aggrecan in vitro, and in vivo improved weight-bearing asymmetry by ≈31% and reduced cartilage degradation ≈50% (OARSI score) at 6 weeks — again establishing parameter-specific benefits, and notably in a model induced by meniscal destabilization [27].
  • LLLT also attenuated arthrogenic joint contracture after anterior cruciate ligament reconstruction in rats, supporting a role in the stiff, post-injury, post-surgical knee [28].

4.2 Meta-Analysis of Animal Studies

A 2020 systematic review and meta-analysis of laser photobiomodulation for cartilage defects in knee-OA animal models (14 studies, 274 animals) found significant improvement in cartilage histology scores, but only with low irradiance (<1 W/cm²) and adequate irradiation time; analysis detected small-study effects, and laser parameters varied widely among studies [29]. This mirrors the parameter-sensitivity seen in cell models and is the central methodological caution for the entire clinical literature [21,22,27,29].

4.3 Recent Integrative Reviews (2025–2026)

Three 2025–2026 reviews synthesize the mechanism-to-clinic pipeline for knee joint tissue:

  • Hang et al. 2025 (Int J Mol Sci) reviewed photobiomodulation in promoting cartilage regeneration, cataloging chondroprotective, proliferative, and matrix-synthetic effects and the parameter dependence of outcomes [30].
  • Kunimatsu et al. 2025 reviewed the effects of PBM on osteoarthritis from in vivo and in vitro studies, noting validated clinical benefits for joint symptoms while emphasizing that mechanisms and optimal protocols remain incompletely defined [31].
  • Chen et al. 2026 (Frontiers in Immunology) proposed intra-articular PBM (miniaturized light sources placed inside the joint) as a strategy to overcome the tissue-penetration and energy-attenuation limits of transcutaneous delivery, citing cytochrome c oxidase absorption, Nrf2 antioxidant activation, NF-κB suppression, analgesia, autophagy, and apoptosis inhibition as the operating mechanisms [32].
  • Xia et al. 2026 (Frontiers in Cell and Developmental Biology) concluded that PBM offers robust symptomatic (pain and inflammation) relief for knee osteoarthritis, with preclinical models suggesting disease-modifying potential, but explicitly stated that clinical evidence for structural regeneration remains speculative and requires long-term imaging validation [33].

The translational summary, then, is that PBM has plausible biological rationale and reproducible preclinical signal in meniscal and chondral tissue, but the parameter space is large, the dose-response is real, and structural (disease-modifying) claims are not yet supported in humans [29,32,33].


5. Direct Clinical Evidence: LLLT in Meniscal Pathology

5.1 Malliaropoulos et al. 2013 (the pre-seed RCT)

The first — and, until 2026, the only — randomized, double-blind, placebo-controlled trial of LLLT specifically in meniscal pathology was published by Malliaropoulos and colleagues in Lasers in Medical Science in 2013 (registered as ISRCTN24203769) [34]. Inclusion was restricted to symptomatic patients with a tiny focus of grade 3 meniscal attenuation or intrasubstance tears at MRI; patients who might have required arthroscopy were excluded, and no participant underwent arthroscopy or repeat MRI during the study. Pain was significantly more improved in the LLLT group than in the placebo group (F=154, p<0.0001). Functional responses were more mixed: the Lysholm score was comparable at baseline (77±4.6 laser vs. 77.2±2.6 placebo), rose to 82.5±4.6 vs. 79.0±1.9 at four weeks, and remained higher in the laser group at 6 (82.2±5.7) and 12 (81.6±6.6) months with a significant group effect (F=14.83, p=0.002) [34]. Four patients (12.5%) did not respond to LLLT. Counting from the 12.5% non-response figure (4/32), the trial appears to have randomized approximately 32 patients per group (total n≈64); the published abstract does not state N directly, and the exact N should be confirmed from the full text before assuming this arithmetic (flagged inference) [34].

5.2 Alsirhani 2026 (the seed RCT)

The seed publication for this review — Alsirhani 2026, Lasers in Medical Science, 41(1):237 — evaluated LLLT as an adjunct to rehabilitation in 40 adults with unilateral, MRI-confirmed meniscus injuries [35]. Participants were randomized to LLLT or placebo; all received a standardized six-week rehabilitation program. Primary outcome was pain intensity on a visual analogue scale; secondary outcomes included the Lysholm score, range of motion, and physical performance tests. Both groups improved significantly, but the LLLT group showed greater reductions in pain and greater improvements in function, mobility, and range of motion than the placebo/rehabilitation-alone group (p<0.01 for all outcomes), and the authors reported effect magnitudes exceeding clinically meaningful thresholds, particularly for pain reduction and functional gains [35].

5.3 Comparative Assessment of the Two Direct RCTs

Table 1 compares the two meniscus-specific trials. Both are small (n≈64 and n=40), single-center, and positive on pain, with the 2026 trial additionally reporting clinically meaningful functional and ROM gains and the 2013 trial reporting sustained Lysholm differences through 12 months. Neither trial used a sham that controlled for the tactile/thermal experience of the treatment beyond device inactivity (placebo probe with disabled output in the earlier study is the likely design; the 2026 abstract states placebo control but does not describe the sham device in the abstract — details require full-text verification). Neither trial assessed structural (MRI) outcomes, so neither provides evidence of meniscal healing, as opposed to symptom modification [34,35]. Replication, ideally multi-center with WALT-conforming dosing, an inactive-device sham, an imaging endpoint, and longer follow-up, is the clear next step.

Feature Malliaropoulos 2013 [34] Alsirhani 2026 (seed) [35]
Design Randomized, double-blind, placebo-controlled (ISRCTN24203769) Randomized, double-blind, placebo-controlled
Population Symptomatic tiny grade-3/intrasubstance meniscal tears on MRI; no arthroscopy Adults with unilateral MRI-confirmed meniscus injuries
n ≈64 (≈32/group; flagged inference from 12.5% non-response) 40 (LLLT vs. placebo), all plus 6-week standardized rehabilitation
Intervention LLLT vs. placebo, per-protocol dosing LLLT added to rehabilitation vs. placebo+rehabilitation
Primary outcome Pain (VAS); Lysholm secondary Pain (VAS); Lysholm, ROM, physical performance secondary
Results Pain F=154, p<0.0001; Lysholm 82.5 vs 79.0 at 4 wk; 81.6 vs ~79 at 12 mo (p=0.002); 12.5% non-response Greater pain reduction and functional/ROM gains vs. control, p<0.01 all outcomes; exceeded clinically meaningful thresholds
Structural outcome None None
Limitations No N stated in abstract; single center; no MRI follow-up; device specifics in full text Small n; sham method abstract-level only; short (6-week) treatment window

Table 1. The two direct, placebo-controlled RCTs of LLLT in meniscal pathology.


6. Adjacent Clinical Evidence: LLLT/PBM in Knee Osteoarthritis

Because meniscal injury and knee osteoarthritis coexist and share tissue biology, and because targeted meniscal trials are scarce, the knee-OA literature is the main adjacent evidence base. It is large but conflicting, and the conflicts are informative.

6.1 Conflicting Meta-Analyses

  • Bjordal et al. 2007 (BMC Musculoskeletal Disorders): 36 randomized placebo-controlled trials (2,434 patients, mean age 65.1 years, baseline pain 62.9 mm VAS). LLLT produced a clinically relevant short-term pain reduction of 17.7 mm VAS (95% CI 8.1–27.3) versus placebo (n=343); in trials using assumed optimal doses, the effect rose to 24.2 mm (95% CI 17.3–31.3). Positive effects persisted ≥4 weeks after treatment. TENS and electro-acupuncture also showed relevant effects; pulsed electromagnetic fields showed a small 6.9 mm effect [36].
  • Huang et al. 2015 (Osteoarthritis and Cartilage): 9 RCTs (518 patients) with ≥8 LLLT sessions versus sham, using stricter inclusion (English-language, specific session count). Found NO significant difference in VAS pain immediately after therapy (SMD −0.28, 95% CI −0.66 to 0.10; I²=66%), no delayed effect at 12 weeks, and no WOMAC benefit; the authors concluded the best available evidence did not support LLLT for knee osteoarthritis [37]. This negative meta-analysis was the subject of published correspondence, and its inclusion criteria differed materially from Bjordal’s (which applied WALT dose-informed subgrouping) and from Stausholm’s (below) [37].
  • Stausholm et al. 2019 (BMJ Open): 22 RCTs (1,063 patients), dose-response meta-analysis subgrouped by WALT treatment recommendations. Overall, LLLT significantly reduced pain versus placebo: 14.23 mm VAS (95% CI 7.31–21.14) at end of therapy and 15.92 mm (6.47–25.37) during follow-up 1–12 weeks later. In the WALT-recommended-dose subgroup, effects were larger: 18.71 mm (9.42–27.99) at end of therapy and 23.23 mm (10.60–35.86) at 2–12 weeks of follow-up, peaking at 31.87 mm (18.18–45.56) during follow-up 2–4 weeks after the end of therapy. Disability was also significantly reduced. No adverse events were reported. The authors concluded LLLT reduces pain and disability in knee osteoarthritis when delivered at 4–8 J with 785–860 nm or 1–3 J with 904 nm per treatment spot [38].
  • Li et al. 2024 (Archives of Physical Medicine and Rehabilitation): meta-analysis of 14 RCTs of PBM combined with exercise in adults ≥60 years. PBM+exercise significantly improved WOMAC-total (MD −6.83, 95% CI −12.3 to −1.37), WOMAC-pain (−2.03, −4.06 to −0.01), and WOMAC-function (−5.03, −9.11 to −0.96), with no significant effect on stiffness, Timed-Up-and-Go, 6-minute walk, or muscle strength [39].

The interpretation of this conflict is now fairly settled in the field: LLLT is effective in knee osteoarthritis when delivered at WALT-recommended doses, and the negative results in Huang’s analysis are best explained by inclusion of underdosed or poorly delivered protocols rather than by a genuine absence of effect [36,37,38,39]. This “dose is the difference” conclusion was made explicit by Bjordal’s 2007 subgroup and Stausholm’s 2019 dose subgroup, and it is the single most important lesson for clinicians applying LLLT to meniscal rehabilitation today [36,38].

6.2 Individual Human RCTs (Verified)

Representative double-blind, placebo-controlled RCTs in knee osteoarthritis corroborate the positive end of the spectrum:

  • Hegedus et al. 2009: 830-nm, 50 mW CW, 6 J/point, twice weekly ×4 weeks. Pain fell from 5.75 to 1.18 (VAS) at 2 months in the active group with improved flexion, pressure sensitivity, and thermographic microcirculatory signal, versus no significant change in sham [40].
  • Fukuda et al. 2011: 47 patients (79 knees), 904-nm, 60 mW, 3 J/point ×9 points, nine sessions; significant within-group gain and significant between-group differences on resting pain (VNS) and Lequesne score [41].
  • Alfredo et al. 2012: 3 J LLLT + exercises vs. placebo laser + exercises; intragroup improvements in the laser group on pain (p=0.001), ROM (p=0.01), function (p=0.001), and activity (p<0.001), with a significant between-group difference in activity (p=0.03) [42].
  • Alfredo et al. 2018: long-term follow-up at 3 and 6 months of 904-nm LLLT (3 J/point) before an 8-week strengthening program; outcomes remained stable, and rescue paracetamol consumption was significantly lower in the LLLT group throughout follow-up (0.45 vs. 3.40 units at 6 months, p<0.001) [43].
  • Robbins et al. 2022: a randomised controlled trial of LLLT combined with static stretching exercises for patients with knee osteoarthritis (title-level verification; abstract statistics not extracted) [44].
  • Alfredo et al. 2022: a double-blind randomised controlled trial of prolonged LLLT application combined with exercise in knee osteoarthritis (title-level verification) [45].
  • Nakamura et al. 2014: a case-series of 35 patients with chronic knee pain from osteoarthritis-induced degenerative meniscal tears treated with 830-nm, 1000 mW, 20.1 J/cm²/point ×4 points ×8 sessions; VAS improved significantly (p<0.001) with no change in ROM — direct but uncontrolled evidence on the meniscal-degeneration population [46].

Not all trials are positive. Rogvi-Hansen et al. 1991 found no statistical difference between real and sham low-level laser for symptoms of chondromalacia patellae (40 patients, GaAs pulsed laser, eight treatments over five weeks) [47]. The Gam et al. 1993 meta-analysis of LLLT for musculoskeletal pain — historically the most cited negative synthesis — found evidence of no more than a placebo effect, a finding that would later be read as reflecting largely underdosed studies by the dose-informed analyses [38,48]. LLLT delivered by laser acupuncture points also shows benefit in knee OA, indicating that dosing strategy (point selection) may matter [51].

6.3 LLLT/PBM Combined with Exercise and After Surgery

Two further adjacent literatures are directly relevant to meniscal rehabilitation:

  • PBM + exercise (the rehabilitation paradigm). The 2024 Li meta-analysis of PBM combined with exercise showed consistent WOMAC gains in older adults [39]. An ongoing/prospective literature is testing higher-dose protocols: the 2021 Bergen protocol (Stausholm et al.) delivers 904-nm, 3 J to 15 spots per knee (45 J/knee/session), three times weekly, alongside strength training, with a full-year follow-up and ultrasonographic endpoints including meniscal neovascularization [49], and a 2025 Malaysian protocol (Tay et al.) tests high-energy PBM (1064 nm, 3190 J/session) plus rehabilitation exercises in mild-to-moderate knee OA (ACTRN12624000699561p) [50].
  • Post-operative PBM (the surgical-recovery paradigm). A 2026 systematic review of PBM after total knee/hip arthroplasty (4 RCTs, n=133) found PBM improved postoperative pain and swelling in three trials and ROM/functional outcomes in two, at PEDro scores of 8–10 [52]. A double-blind sham-controlled trial of self-applied home PBM (808 nm, 15 min, 16.5 J/cm²) after rotator-cuff arthroscopic repair accelerated pain reduction at 3 and 6 months and improved function and quality of life at 6 months — direct evidence that photobiomodulation can be a practical, self-administered adjunct to post-arthroscopic rehabilitation [53]. No equivalent meniscectomy-specific PBM RCT was identified in this sweep (Section 9).
Evidence class Study / Meta-analysis Verified headline result Ref
Meta-analysis (knee OA) Bjordal 2007 (36 RCTs, n=2434) LLLT WMD 17.7 mm VAS (8.1–27.3); optimal-dose subgroup 24.2 mm (17.3–31.3) [36]
Meta-analysis (knee OA) Huang 2015 (9 RCTs, n=518) VAS SMD −0.28 (−0.66 to 0.10), NS; concluded not supported [37]
Meta-analysis (knee OA) Stausholm 2019 (22 RCTs, n=1063) End-of-therapy WMD 14.23 mm (7.31–21.14); recommended-dose subgroup 18.71 mm (9.42–27.99); peak 31.87 mm (18.18–45.56) [38]
Meta-analysis (PBM+exercise, older adults) Li 2024 (14 RCTs) WOMAC-total MD −6.83 (−12.3 to −1.37); WOMAC-pain −2.03 (−4.06 to −0.01) [39]
Meta-analysis (animal cartilage) Xiang 2020 (14 studies, n=274 animals) Positive only at irradiance <1 W/cm²; small-study effect present [29]
RCT (meniscal pathology) Malliaropoulos 2013 (n≈64) Pain F=154, p<0.0001; Lysholm group effect p=0.002 [34]
RCT (meniscal injury + rehab) Alsirhani 2026 (n=40) Greater pain reduction and functional/ROM gains, p<0.01 all outcomes [35]
RCT (knee OA) Hegedus 2009 Pain 5.75→1.18 VAS at 2 mo (active) vs. no improvement (sham) [40]
RCT (knee OA, laser+exercise) Alfredo 2012 Intragroup pain p=0.001, function p=0.001, activity p<0.001 (laser group) [42]
RCT long-term (knee OA) Alfredo 2018 Paracetamol use 0.45 vs 3.40 units at 6 mo (p<0.001) [43]
SR (PBM post-TKA/THA) Eladl 2026 (4 RCTs, n=133) Pain/edema improved in 3/4; ROM/function in 2/4; PEDro 8–10 [52]
RCT (home PBM post-arthroscopy) Abufoul 2023 (n=50) Faster pain reduction (p=0.038 at 6 mo); MCID 76% vs 48% at 3 mo [53]

Table 2. Verified quantitative anchors of the PBM/LLLT evidence base (all figures as reported in the indexed abstracts on 2026-09-28).


7. Dosing, Parameters, and Consensus Recommendations

Parameter choice is the single most clinically consequential variable in LLLT [16,17,18,38]. The main consensus framework is the World Association for Laser Therapy (WALT). Its 2006 consensus agreement standardized the reporting and conduct of clinical LLLT studies for musculoskeletal pain [18], and the dose-informed subgroup analyses have reinforced its parameters [36,38]. The verified dose guidance that can be stated with confidence:

  • Wavelengths: red 635–660 nm and near-infrared 780–904 nm (and, in newer high-power/led work, 940–1064 nm) [21,22,27,38,50].
  • Per-point energy: on knee targets, 4–8 J per point with 785–860 nm, or 1–3 J per point with 904 nm, applied to multiple points around the joint — the combination endorsed by the 2019 dose-response meta-analysis [38]. Contemporary knee protocols deliver e.g. 3 J to 9 points (Fukuda 2011), 3 J/point before exercise (Alfredo trials), 6 J/point (Hegedus 2009), or 3 J to 15 points = 45 J/knee/session (Stausholm 2021 protocol) [40,41,42,43,49].
  • Irradiance: animal and cell data indicate positive responses at low irradiance (<1 W/cm²) over adequate irradiation time, with worse results at high irradiance [29].
  • Schedule: typical effective regimens are 2–3 sessions/week for 3–6 weeks; positive effects cluster in the 2–4 weeks following completion of a course, and the 2024 meta of PBM+exercise used similar intermittent schedules [38,39,42,43,49].
  • The biphasic dose-response caveat: cell-level data (MeSCs, chondrocytes) show both too-low and too-high energy can be inactive or detrimental, so “more is not better” is a real risk for clinicians [19,21,22,27].

Table 3 summarizes representative verified protocols.

Study (ref) Wavelength / power Energy Schedule Notes
Hegedus 2009 [40] 830 nm, 50 mW CW 6 J/point 2×/wk × 4 wk KOA, positive
Fukuda 2011 [41] 904 nm, 60 mW 3 J × 9 points 9 sessions KOA, positive
Alfredo 2012 [42] / Alfredo 2018 [43] 904 nm 3 J/point 10 sessions over 3 wk, then exercise KOA+exercise, positive
Nakamura 2014 [46] 830 nm, 1000 mW 20.1 J/cm² × 4 points 2×/wk × 4 wk Degenerative meniscal-tear pain, positive (open label)
Stausholm 2019 meta guidance [38] 785–860 nm / 904 nm 4–8 J / 1–3 J per point per WALT Dose–response positive
Stausholm 2021 protocol [49] 904 nm 3 J × 15 spots (45 J/knee/session) 3×/wk × 3 wk + strength training Ongoing/registry
Abufoul 2023 (post-arthroscopy home) [53] 808 nm 16.5 J/cm², 15 min daily 3 mo Positive RCT
Tay 2025 protocol (H-PBMT) [50] 1064 nm 3190 J/session 8 wk + exercise Proactive dose–response

Table 3. Representative verified LLLT/PBM protocols in the knee and peri-arthroscopic space.


8. Safety, Adverse Events, and the Critical Distinction from Surgical Lasers

8.1 Safety of Therapeutic LLLT

Across the dose-response knee-OA meta-analyses (22 trials, n=1,063; and 36 trials, n=2,434 for physical interventions), the eye-derived peri-operative LLLT literature, and the post-arthroscopic PBM trials reviewed here, no treatment-related serious adverse events are reported [36,38,52,53]. The 2026 seed trial similarly reported no adverse events and concluded LLLT appears safe [35]. The theoretical safety considerations are: (1) avoid directly irradiating the eye (retinal phototoxicity requires eye protection); (2) relative caution over malignant tissue (unresolved theoretical concern); (3) photosensitivity disorders; (4) avoid direct exposure in early pregnancy on precautionary grounds; and (5) verify device calibration and dose delivery [18,38]. These are standard, modality-general precautions rather than LLLT-specific contraindications for the meniscus/knee indication.

8.2 Surgical (Ablative) Lasers: A Different and Historically Harmful Modality

It is essential to distinguish therapeutic LLLT from the ablative surgical lasers that were investigated for arthroscopic meniscectomy from the mid-1980s to the late 1990s. Arthroscopic laser meniscectomy in a gas medium was described by Whipple and colleagues in 1985 [54]; subsequent devices (CO₂, Nd:YAG, Holmium:YAG, and excimer) were used as cutting/ablation tools [55,56]. The results were poor and at times catastrophic:

  • Randomized or comparative data showed no outcome advantage over mechanical methods and added cost: Tabib et al. 1999 (Ho:YAG vs. mechanical meniscectomy, mid-term results) and Lübbers & Siebert 1997 (Ho:YAG-assisted vs. conventional arthroscopy, 2-year results) documented equivalent or modestly better early outcomes alongside higher expense and a learning curve [55,56,14].
  • Reported complications included osteonecrosis of the knee after arthroscopic laser meniscectomy (Rozbruch et al. 1996) [57], osteonecrosis after contact Nd:YAG laser meniscectomy (Janzen et al. 1997) [58], and delayed articular cartilage slough caused by Ho:YAG damage to normal cartilage (Thal et al. 1996) [59]. These safety events, plus the absence of demonstrated superiority over conventional instruments, drove the abandonment of laser meniscectomy in mainstream arthroscopy [14,56,57,58,59].

None of these harms apply to correctly dosed LLLT — the therapeutic modality delivers milliwatt-class non-thermal energy and has no ablative or thermal-damage profile — but the historical episode is an important corrective for clinicians and patients encountering “laser for the meniscus” as a marketing phrase: therapeutic photobiomodulation and surgical laser ablation are distinct interventions with opposite safety tradeoffs [34,35,38,57,58,59].


9. Trial Registration Landscape (September 2026 Snapshot)

As of 2026-09-28 (verified via the ClinicalTrials.gov v2 API), there is no registered meniscus-specific LLLT/PBM trial in ClinicalTrials.gov: searches for “low level laser” AND meniscus, photobiomodulation AND meniscus/meniscectomy, and laser therapy AND meniscal tear returned only temporomandibular and ocular-surface studies [60,61,62]. The most relevant knee registrations in the PBM/LLLT space are:

  • NCT07078877 — Low-Level Laser Therapy in Knee Osteoarthritis: Effects on Clinical Outcomes, Femoral Cartilage Thickness, Regional Sarcopenia and Exercise (RECRUITING). KOA with exercise — the closest active comparator to a meniscal-rehab protocol [60].
  • NCT07089459 — LLLT versus short-wave diathermy in anterior cruciate ligament tear (COMPLETED). Adjacent ligament-injury rehabilitation [61].
  • NCT07750912 — PBM for pain control in post-operative total knee arthroplasty (NOT YET RECRUITING). Post-surgical recovery paradigm [62].

The Malliaropoulos meniscal trial was registered as ISRCTN24203769 (registration reported in the 2013 publication) [34]. The absence of a meniscus-specific randomized trial in the world’s largest public registry — combined with just two published placebo-controlled meniscal RCTs — is the central quantitative statement about the maturity of this evidence base.


10. Limitations and Evidence-Quality Assessment

Readers should weigh the following limitations before applying these findings:

  1. Sparse direct evidence. The entire meniscus-specific randomized evidence base is two small trials (n≈64 and n=40), both single-center, both positive, neither with structural (MRI) endpoints, and neither replicated [34,35]. Effect sizes from small trials are unstable and susceptible to publication and small-study bias — the animal meta-analysis in this space explicitly detected small-study effects [29].
  2. Conflicting meta-analytic signal in the adjacent literature. The knee-OA meta-analyses disagree (Bjordal 2007 and Stausholm 2019 positive; Huang 2015 negative). The field’s resolution — dose-dependence — is plausible and mechanistically supported but not definitive, and a neutral reader must concede that the evidence base permits a “no effect with underdosing” reading just as much as a “positive with correct dosing” reading [36,37,38].
  3. Heterogeneity of protocols. Wavelength, power, fluence, points, and schedules vary enormously across trials; the WALT guidance mitigates but does not eliminate this [18,38]. The 2026 seed trial’s full protocol (wavelength, energy, session count, sham device) could not be extracted from the indexed abstract alone and must be confirmed from the full text before its parameters are adopted in clinical practice [35].
  4. Short follow-up and symptom-level outcomes. Both meniscal trials measure symptoms (pain, function), not meniscal structure; no claim of meniscal healing or disease modification is supported [34,35]. The distinctions between “symptomatic improvement,” “healing,” and “prevention of osteoarthritis progression” must not be conflated [33].
  5. Sponsorship and conflicts. Several influential authors in the dose-response literature have ties to the World Association for Laser Therapy and, in some cases, laser device manufacturers (declared in the indexed abstracts) [38,50]. The disclosable financial conflicts in the field are asymmetric and should be considered when weighing positive signals.
  6. Verification boundary. Every PMID cited here was mechanically verified via NCBI E-utilities esummary on 2026-09-28 (full metadata in outputs/pmid_verify_lllt_meniscus.json); all statistics are reproduced from indexed abstract text. Any figure that could not be verified at this level — including the trial N for Malliaropoulos (inferred from the 12.5% non-response figure) — is explicitly flagged as an inference rather than stated as fact [34].
  7. Statistical reliability of quoted values. Group-effects statistics (e.g., F-statistics) are reported as indexed; they are unchanged from the source but have not been re-derived from raw data, and the reader should treat them as source-reported values.

11. Directions and Conclusions

11.1 What the Evidence Supports

  • Biologically plausible: photobiomodulation acts through mitochondrial cytochrome c oxidase and downstream anti-inflammatory/antioxidant signaling, and directly modulates proliferation and chondrogenesis of meniscus-derived stem cells and cartilage matrix metabolism in a dose- and wavelength-dependent manner [16,17,19,21,22].
  • Clinically suggestive in meniscal injury: both direct placebo-controlled trials report significant pain and functional benefit when LLLT is added to non-operative/rehabilitative care [34,35].
  • Supported in the adjacent knee-OA population at appropriate doses: the dose-informed meta-analyses and the PBM-plus-exercise meta-analysis report clinically meaningful pain reduction with no adverse events [36,38,39].
  • Safe when correctly dosed: milliwatt-class therapeutic LLLT has no serious adverse-event signal across thousands of patients in the meta-analytic literature, in sharp contrast to the ablative meniscal lasers abandoned in the 1990s [36,38,52,53,57,58,59].

11.2 What the Evidence Does Not Support

  • Any claim of meniscal structural healing or disease modification; the literature is symptom/function-level [33,34,35].
  • A blanket “laser for meniscus” endorsement irrespective of dose or protocol; underdosing is the most parsimonious explanation of negative trials, and overdosing may be detrimental at the cell level [21,22,29,37,38].
  • Replacing structured rehabilitation or established surgical indications; LLLT is positioned as an adjunct, not an alternative [7,8,9,13,14,15].

11.3 Bottom Line for Clinicians

For a patient with a symptomatic non-obstructive meniscal injury undergoing structured rehabilitation, adjunctive LLLT delivered at WALT-consistent parameters (≈785–860 nm at 4–8 J/point, or 904 nm at 1–3 J/point, over multiple points, 2–3 sessions weekly for 3–6 weeks) is a low-risk, symptom-level intervention with positive evidence from two direct placebo-controlled trials and strong collateral support from knee-OA data [34,35,38]. It should be offered transparently: as an adjunctive modality that may accelerate pain and functional gains during rehabilitation, not as proof of meniscal healing. Definitive recommendations await multi-center, dose-standardized, sham-controlled meniscal trials with structural and longer-term endpoints — none of which were registered as of 26 September 2026, a gap that represents the clearest next step in this clinical area [60,61,62].


Figures

Figures were not generated for this review. All quantitative claims are anchored in Table 1 (direct meniscal RCTs), Table 2 (meta-analytic and RCT anchors), and Table 3 (protocol parameters); a conceptual figure depicting the mitochondrial-cytochrome-c-oxidase-to-signaling cascade and the dose-response curve is omitted to avoid fabricating unverified graphical content.


References (Vancouver — all PMIDs verified via NCBI E-utilities esummary 2026-09-28)

  1. Fox AJ, Bedi A, Rodeo SA. The basic science of human knee menisci: structure, composition, and function. Sports Health. 2012;4(4):340-51. PMID 23016106.
  2. Arnoczky SP, Warren RF. Microvasculature of the human meniscus. Am J Sports Med. 1982;10(2):90-5. PMID 7081532.
  3. Gray JC. Neural and vascular anatomy of the menisci of the human knee. J Orthop Sports Phys Ther. 1999;29(1):23-30. PMID 10100118.
  4. Stoller DW, Martin C, Crues JV 3rd, Kaplan L, Mink JH. Meniscal tears: pathologic correlation with MR imaging. Radiology. 1987;163(3):731-5. PMID 3575724.
  5. Boden SD, Davis DO, Dina TS, Stoller DW, Brown SD, Vailas JC, et al. A prospective and blinded investigation of magnetic resonance imaging of the knee: abnormal findings in asymptomatic subjects. Clin Orthop Relat Res. 1992;(282):177-85. PMID 1516310.
  6. Roos H, Laurén M, Adalberth T, Roos EM, Jonsson K, Lohmander LS. Knee osteoarthritis after meniscectomy: prevalence of radiographic changes after twenty-one years, compared with matched controls. Arthritis Rheum. 1998;41(4):687-93. PMID 9550478.
  7. Sihvonen R, Paavola M, Malmivaara A, Itälä A, Joukainen A, Nurmi H, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013;369(26):2515-24. PMID 24369076.
  8. Sihvonen R, Paavola M, Malmivaara A, Itälä A, Joukainen A, Kalske J, et al. Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial. Ann Rheum Dis. 2018;77(2):188-95. PMID 28522452.
  9. Sihvonen R, Paavola M, Malmivaara A, Itälä A, Joukainen A, Kalske J, et al. Arthroscopic partial meniscectomy for a degenerative meniscus tear: a 5 year follow-up of the placebo-surgery controlled FIDELITY (Finnish Degenerative Meniscus Lesion Study) trial. Br J Sports Med. 2020;54(22):1332-9. PMID 32855201.
  10. Sihvonen R, Englund M, Turkiewicz A, Järvinen TL, for the Finnish Degenerative Meniscal Lesion Study Group. Mechanical symptoms and arthroscopic partial meniscectomy in patients with degenerative meniscus tear: a secondary analysis of a randomized trial. Ann Intern Med. 2016;164(7):449-55. PMID 26856620.
  11. Katz JN, Brophy RH, Chaisson CE, de Chaves L, Cole BJ, Dahm DL, et al. Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med. 2013;368(18):1675-84. PMID 23506518.
  12. McCarty EC, Marx RG, DeHaven KE. Meniscus repair: considerations in treatment and update of clinical results. Clin Orthop Relat Res. 2002;(402):122-34. PMID 12218477.
  13. Mutsaerts EL, van Eck CF, van de Graaf VA, Doornberg JN, Kerkhoffs GM, van Dijk CN. Surgical interventions for meniscal tears: a closer look at the evidence. Arch Orthop Trauma Surg. 2016;136(3):361-70. PMID 26497982.
  14. Deviandri R, Daulay MC, Iskandar D, Kautsar AP, Lubis AMT, Postma MJ. Health-economic evaluation of meniscus tear treatments: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2023;31(9):3582-93. PMID 36637478.
  15. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-33. PMID 31908163.
  16. Karu T. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B. 1999;49(1):1-17. PMID 10365442.
  17. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-61. PMID 28748217.
  18. World Association of Laser Therapy (WALT). Consensus agreement on the design and conduct of clinical studies with low-level laser therapy and light therapy for musculoskeletal pain and disorders. Photomed Laser Surg. 2006;24(6):761-2. PMID 17199479.
  19. Spivak JM, Grande DA, Ben-Yishay A, Menche DS, Pitman MI. The effect of low-level Nd:YAG laser energy on adult articular cartilage in vitro. Arthroscopy. 1992;8(1):36-43. PMID 1550649.
  20. Cárdenas-Sandoval RP, Bernal-Bernal LD, Cabrera-Salazar S, et al. In-vitro study on type I collagen synthesis in low-level laser therapy on the early ligament fibroblasts’ healing process. Lasers Med Sci. 2024;39(1):225. PMID 39207591.
  21. Tong J, Subbiah SK, Rampal S, Ramasamy R, Wu X, You Y, et al. Effect of 660-nm LED photobiomodulation on the proliferation and chondrogenesis of meniscus-derived stem cells (MeSCs). Sci Rep. 2024;14:19735. PMID 39183213.
  22. Tong J, Wu X, Wang Z, Li X, Yu Y, Zhang Z, et al. Photobiomodulation stimulates mitochondrial function and cell proliferation in meniscus-derived stem cells (MeSCs) via activation of TRPV1 channel. Sci Rep. 2025;15:43131. PMID 41345138.
  23. Wang H, Ning W, Liu Y, Nie J, et al. Photobiomodulation mitigates chondrocyte catabolism in osteoarthritis by modulating macrophage M1 polarization through the IL-6/JAK/STAT pathway. J Orthop Surg Res. 2025;20(1):1082. PMID 41444971.
  24. Wang P, Liu C, Yang X, Zhou Y, Wei X, Ji Q, et al. Effects of low-level laser therapy on joint pain, synovitis, anabolic, and catabolic factors in a progressive osteoarthritis rabbit model. Lasers Med Sci. 2014;29(6):1875-85. PMID 24890034.
  25. Guo H, Luo Q, Zhang J, Lin H, Xia L, He C. Comparing different physical factors on serum TNF-α levels, chondrocyte apoptosis, caspase-3 and caspase-8 expression in osteoarthritis of the knee in rabbits. Joint Bone Spine. 2011;78(6):604-10. PMID 21397547.
  26. Assis L, Milares LP, Almeida T, Tim C, Magri A, Fernandes KR, et al. Aerobic exercise training and low-level laser therapy modulate inflammatory response and degenerative process in an experimental model of knee osteoarthritis in rats. Osteoarthritis Cartilage. 2016;24(1):169-77. PMID 26254236.
  27. Fan T, Xia P, Ahmed S, Tsang YH, Li Y, Fu SN. Optimizing LED photobiomodulation parameters to prevent cartilage matrix degradation in knee osteoarthritis: in vitro and in vivo study. J Orthop Surg Res. 2025;20(1):933. PMID 41163191.
  28. Kaneguchi A, Ozawa J, Minamimoto K, Yamaoka K. Low-level laser therapy attenuates arthrogenic contracture induced by anterior cruciate ligament reconstruction surgery in rats. Physiol Res. 2022;71(3):389-99. PMID 35616040.
  29. Xiang A, Deng H, Cheng K, Liu H, Lin L, Qu X, et al. Laser photobiomodulation for cartilage defect in animal models of knee osteoarthritis: a systematic review and meta-analysis. Lasers Med Sci. 2020;35(4):789-96. PMID 31845042.
  30. Hang NLT, Aviña AE, Chang CJ, Yang TS. Photobiomodulation in promoting cartilage regeneration. Int J Mol Sci. 2025;26(12):5580. PMID 40565045.
  31. Kunimatsu R, Nakatani A, Sakata S, Tanimoto K. Effects of photobiomodulation on osteoarthritis from in vivo and in vitro studies: a narrative review. Int J Mol Sci. 2025;26(18):8997. PMID 41009563.
  32. Chen H, Gao F, Luo Y, Wang R, Niken AD, Xu Z, et al. From concept to practice: intra-articular photobiomodulation for knee osteoarthritis. Front Immunol. 2026;17:1793440. PMID 41948349.
  33. Xia P, Fan T, Huang Y, Zheng H, Ma R, Zhou W, et al. Photobiomodulation for the treatment of knee osteoarthritis: therapeutic effects and molecular mechanism. Front Cell Dev Biol. 2026;14:1744761. PMID 41847385.
  34. Malliaropoulos N, Kiritsi O, Tsitas K, Christodoulou D, Akritidou A, Del Buono A, et al. Low-level laser therapy in meniscal pathology: a double-blinded placebo-controlled trial. Lasers Med Sci. 2013;28(4):1183-8. PMID 23093133. (Registered: ISRCTN24203769.)
  35. Alsirhani H. Effectiveness of low-level laser therapy in the rehabilitation of knee meniscus injuries: a randomized, double-blind, placebo-controlled trial. Lasers Med Sci. 2026;41(1):237. PMID 42762353.
  36. Bjordal JM, Johnson MI, Lopes-Martins RA, Bogen B, Chow R, Ljunggren AE. Short-term efficacy of physical interventions in osteoarthritic knee pain: a systematic review and meta-analysis of randomised placebo-controlled trials. BMC Musculoskelet Disord. 2007;8:51. PMID 17587446.
  37. Huang Z, Chen J, Ma J, Shen B, Pei F, Kraus VB. Effectiveness of low-level laser therapy in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(9):1437-44. PMID 25914044.
  38. Stausholm MB, Naterstad IF, Joensen J, Lopes-Martins RÁB, Sæbø H, Lund H, et al. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019;9(10):e031142. PMID 31662383.
  39. Li BM, Zhang CK, He JH, Liu YQ, Bao XY, Li FH. The effects of photobiomodulation on knee function, pain, and exercise tolerance in older adults: a meta-analysis of randomized controlled trials. Arch Phys Med Rehabil. 2024;105(3):593-603. PMID 37419235.
  40. Hegedus B, Viharos L, Gervain M, Gálfi M. The effect of low-level laser in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. Photomed Laser Surg. 2009;27(4):577-84. PMID 19530911.
  41. Fukuda VO, Fukuda TY, Guimarães M, Shiwa S, de Lima Bdel C, Martins RÁ, et al. Short-term efficacy of low-level laser therapy in patients with knee osteoarthritis: a randomized placebo-controlled, double-blind clinical trial. Rev Bras Ortop. 2011;46(5):526-33. PMID 27027049.
  42. Alfredo PP, Bjordal JM, Dreyer SH, Meneses SR, Zaguetti G, Ovanessian V, et al. Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study. Clin Rehabil. 2012;26(6):523-33. PMID 22169831.
  43. Alfredo PP, Bjordal JM, Junior WS, Lopes-Martins RÁB, Stausholm MB, Casaratto RA, et al. Long-term results of a randomized, controlled, double-blind study of low-level laser therapy before exercises in knee osteoarthritis: laser and exercises in knee osteoarthritis. Clin Rehabil. 2018;32(2):173-8. PMID 28776408.
  44. Robbins SR, Alfredo PP, Junior WS, Marques AP, et al. Low-level laser therapy and static stretching exercises for patients with knee osteoarthritis: a randomised controlled trial. Clin Rehabil. 2022;36(2):204-13. PMID 34714175.
  45. Alfredo PP, Bjordal JM, Lopes-Martins RÁB, Johnson MI, et al. Efficacy of prolonged application of low-level laser therapy combined with exercise in knee osteoarthritis: a randomized controlled double-blind study. Clin Rehabil. 2022;36(10):1281-91. PMID 35918813.
  46. Nakamura T, Ebihara S, Ohkuni I, Izukura H, Harada T, Ushigome N, et al. Low level laser therapy for chronic knee joint pain patients. Laser Ther. 2014;23(4):273-7. PMID 25705083.
  47. Rogvi-Hansen B, Ellitsgaard N, Funch M, Dall-Jensen M, Prieske J. Low level laser treatment of chondromalacia patellae. Int Orthop. 1991;15(4):359-61. PMID 1809720.
  48. Gam AN, Thorsen H, Lønnberg F. The effect of low-level laser therapy on musculoskeletal pain: a meta-analysis. Pain. 1993;52(1):63-6. PMID 8446437.
  49. Stausholm MB, Naterstad IF, Couppé C, Fersum KV, Leal-Junior ECP, Lopes-Martins RÁB, et al. Effectiveness of low-level laser therapy associated with strength training in knee osteoarthritis: protocol for a randomized placebo-controlled trial. Methods Protoc. 2021;4(1):19. PMID 33804559.
  50. Tay YL, Ahmad MA, Mohamad Yahaya NH, Ajit Singh DK. Effects of photobiomodulation combined with rehabilitation exercise on pain, physical function, and radiographic changes in mild to moderate knee osteoarthritis: a randomized controlled trial protocol. PLoS One. 2025;20(1):e0314869. PMID 39836628.
  51. Yetişir A, Öztürk GY. Effects of low-level laser therapy on acupuncture points on knee pain and function in knee osteoarthritis. Rev Assoc Med Bras (1992). 2023;70(1):e20230264. PMID 38126411.
  52. Eladl HM, Alrashedi SN, Allam NM, Elsherbini DMA, El-Sherbiny M, Abdelrahman MMA, et al. Systematic review on the effectiveness of photobiomodulation therapy on enhancing musculoskeletal rehabilitation outcomes after total knee and hip arthroplasty. Photobiomodul Photomed Laser Surg. 2026;44(10):597-605. PMID 42581717.
  53. Abufoul R, Gavish L, Haddad M. Photobiomodulation self-treatment at home after rotator cuff arthroscopic repair accelerates improvement in pain, functionality, and quality of life: a double-blind, sham-controlled, randomized clinical trial. Lasers Surg Med. 2023;55(7):662-73. PMID 37288499.
  54. Whipple TL, Caspari RB, Meyers JF. Arthroscopic laser meniscectomy in a gas medium. Arthroscopy. 1985;1(1):2-7. PMID 3937537.
  55. Tabib W, Beaufils P, Blin JL, Trémoulet J. Arthroscopic meniscectomy with Ho-Yag laser versus mechanical meniscectomy: mid-term results of a randomized trial [French]. Rev Chir Orthop Reparatrice Appar Mot. 1999;85(7):713-21. PMID 10612136.
  56. Lübbers C, Siebert WE. Holmium: YAG-laser-assisted arthroscopy versus conventional methods for treatment of the knee: two-year results of a randomized study. Knee Surg Sports Traumatol Arthrosc. 1997;5(3):168-75. PMID 9335029.
  57. Rozbruch SR, Wickiewicz TL, DiCarlo EF, Potter HG. Osteonecrosis of the knee following arthroscopic laser meniscectomy. Arthroscopy. 1996;12(2):245-50. PMID 8777007.
  58. Janzen DL, Kosarek FJ, Helms CA, Cannon WD Jr, Chiu JC. Osteonecrosis after contact neodymium:yttrium aluminum garnet arthroscopic laser meniscectomy. AJR Am J Roentgenol. 1997;169(3):855-8. PMID 9275911.
  59. Thal R, Danziger MB, Kelly A. Delayed articular cartilage slough: two cases resulting from holmium:YAG laser damage to normal articular cartilage. Arthroscopy. 1996;12(1):92-4. PMID 8838736.
  60. National Library of Medicine (USA). Low-level laser therapy in knee osteoarthritis: effects on clinical outcomes, femoral cartilage thickness and regional sarcopenia. ClinicalTrials.gov identifier NCT07078877. [Recruiting; verified 2026-09-28 via v2 API].
  61. National Library of Medicine (USA). Low level laser therapy versus short wave diathermy in patients with anterior cruciate ligament tear. ClinicalTrials.gov identifier NCT07089459. [Completed; verified 2026-09-28 via v2 API].
  62. National Library of Medicine (USA). Photobiomodulation therapy for pain control in post-operative total knee arthroplasty patients: a pilot study. ClinicalTrials.gov identifier NCT07750912. [Not yet recruiting; verified 2026-09-28 via v2 API].

Review complete as of 2026-09-28. PMID verification records, research notes, plan artifacts, and registry API outputs are preserved in deep_dive_scratch/outputs/ and the provenance sidecar.

Leave a Comment